US2020268874A1PendingUtilityA1
Methods of Treating and Preventing Infections
Assignee: LONGHORN VACCINES & DIAGNOSTICS LLCPriority: Aug 27, 2007Filed: Mar 8, 2020Published: Aug 27, 2020
Est. expiryAug 27, 2027(~1.1 yrs left)· nominal 20-yr term from priority
C07K 16/108G16B 99/00C12N 2760/16134C07K 16/1289C07K 2319/42C07K 14/35C07K 2319/40A61K 2039/6068A61K 2039/575A61K 2039/6043A61K 2039/70A61K 2039/55566A61K 2039/5254A61K 39/12A61K 2039/53A61K 39/04C07K 14/005A61K 2039/543C12N 7/00A61K 2039/6037C12N 2760/16161A61K 39/145C07K 14/33A61K 2039/545A61K 2039/525C12N 2760/16122A61K 2039/5252C07K 16/1018
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition, the invention relates to vaccines comprising composite antigens and to method for treating and preventing an infection.
Claims
exact text as granted — not AI-modified1 . A method of treating or preventing an infection of an influenza virus comprising:
providing an immunogenic composition that contains a peptide which comprises an amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 1-116; and a T-cell stimulating epitope; and administering the immunogenic composition to a patient to generate an immunological response to the infection.
2 . The method of claim 1 , wherein the influenza virus comprises one or more of H1N1, H1N7, H2N2, H3N1, H3N2, H3N8, H5N1, H5N2, H5N3, H5N8, H5N9, H7N1, H7N2, H7N3, H7N4, H7N7 or H9N2.
3 . The method of claim 1 , wherein the peptide comprises the sequence of one or more of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 12, SEQ ID NO 13, SEQ ID NO 14, SEQ ID NO 15, SEQ ID NO 16, SEQ ID NO 17, SEQ ID NO 18, SEQ ID NO 19, SEQ ID NO 20, SEQ ID NO 47, SEQ ID NO 52, SEQ ID NO 53, and SEQ ID NO 54.
4 . An immunogenic composition that contains a peptide which comprises an amino acid sequence that is at least 95% identical to any one or more of SEQ ID NOs: 1-116; and a T-cell stimulating epitope.
5 . The composition of claim 4 , which further contains an adjuvant.
6 .- 45 . (canceled)Join the waitlist — get patent alerts
Track US2020268874A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.